A Comparison of Breast Surgeon and Nomogram-Generated Risk Predictions of Sentinel and Non-Sentinel Node Metastases

Luisa Sugaya, Paulo R. de Alcantara Filho, Bruna Salani Mota, Sujata Patil, Kimberly J. Van Zee, José Luiz B. Bevilacqua

Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
Department of Epidemiology and Biostatistics, Memorial Sloan-KetteringCancer Center, New York, USA.
Hospital Sirio-Libanes, Sao Paulo, Brazil.

DOI: 10.4236/jct.2013.47A001                

Abstract

Memorial Sloan-Kettering Cancer Center (MSKCC) has developed 2 nomograms: the Sentinel Lymph Node Nomogram (SLNN), which is used to predict the likelihood of sentinel lymph node (SLN) metastases in patients with invasive breast cancer, and the Non-Sentinel Lymph Node Nomogram (NSLNN), which is used to predict the likelihood of residual axillary disease after a positive SLN biopsy. Our purpose was to compare the accuracy of MSKCC nomogram predictions with those made by breast surgeons. Two questionnaires were built with characteristics of two sets of 33 randomly selected patients from the MSKCC Sentinel Node Database. The first included only patients with invasive breast cancer, and the second included only patients with invasive breast cancer and positive SLN biopsy. 26 randomly selected Brazilian breast surgeons were asked about the probability of each patient in the first set having SLN metastases and each patient in the second set having additional non-SLN metastases. The predictions of the nomograms and breast surgeons were compared. There was no correlation between nomogram risk predictions and breast surgeon risk prediction estimates for either the SLNN or the NSLNN. The area under the receiver operating characteristics curves (AUCs) were 0.871 and 0.657 for SLNN and breast surgeons, respectively (p < 0.0001), and 0.889 and 0.575 for the NSLNN and breast surgeons, respectively (p < 0.0001). The nomograms were significantly more accurate as prediction tools than the risk predictions of breast surgeons in Brazil. This study demonstrates the potential utility of both nomograms in the decision-making process for patients with invasive breast cancer.

Keywords

Sentinel Lymph Node Biopsy; Nomogram; Predictions; Breast Cancer; Completion Axillary Lymph Node Dissection

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	F. Andre, et al., “Breast Cancer with Synchronous Metastases: Trends in Survival during a 14-Year Period,” Journal of Clinical Oncology, Vol. 22, No. 16, 2004, pp. 3302-3308. doi:10.1200/JCO.2004.08.095
[2]	N. G. Coburn, et al., “Decreased Breast Cancer Tumor Size, Stage, and Mortality in Rhode Island: An Example of a Well-Screened Population,” Cancer Control Journal, Vol. 11, No. 4, 2004, pp. 222-230.
[3]	A. E. Giuliano, et al., “Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial,” Annals of Surgery, Vol. 252, No. 3, 2010, pp. 426-432.
[4]	J. M. Guenther, et al., “Axillary Dissection Is Not Required for All Patients with Breast Cancer and Positive Sentinel Nodes,” Archives of Surgery, Vol. 138, No. 1, 2003, pp. 52-56. doi:10.1001/archsurg.138.1.52
[5]	J. S. Fant, et al., “Preliminary Outcome Analysis in Patients with Breast Cancer and a Positive Sentinel Lymph Node Who Declined Axillary Dissection,” Annals of Surgical Oncology, Vol. 10, No. 2, 2003, pp. 126-130. doi:10.1245/ASO.2003.04.022
[6]	A. M. Naik, et al., “The Risk of Axillary Relapse after Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable with That of Axillary Lymph Node Dissection: A Follow-Up Study of 4008 Procedures,” Annals of Surgery, Vol. 240, No. 3, 2004, pp. 462-468. doi:10.1097/01.sla.0000137130.23530.19
[7]	R. Ramjeesingh, et al., “Prediction of Involvement of Sentinel and Nonsentinel Lymph Nodes in a Canadian Population with Breast Cancer,” Canadian Journal of Surgery, Vol. 52, No. 1, 2009, pp. 23-30.
[8]	J. Park, et al., “A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-Positive Breast Cancer Patients Is Associated with the Use of a Multivariate Nomogram,” Annals of Surgery, Vol. 245, No. 3, 2007, pp. 462-468. doi:10.1097/01.sla.0000250439.86020.85
[9]	C. Reynolds, et al., “Sentinel Lymph Node Biopsy with Metastasis: Can Axillary Dissection Be Avoided in Some Patients with Breast Cancer? Journal of Clinical Oncology, Vol. 17, No. 6, 1999, pp. 1720-1726.
[10]	W. P. Weber, et al., “Sentinel Lymph Node Frozen Section and Axillary Dissection for Breast Cancer: Are These Procedures Becoming Obsolete? Annals of Surgical Oncology, Vol. 18, Suppl. 1, 2011, p. S32.
[11]	K. Y. Bilimoria, et al., “Comparison of Sentinel Lymph Node Biopsy Alone and Completion Axillary Lymph Node Dissection for Node-Positive Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 18, 2009, pp. 2946-2953. doi:10.1200/JCO.2008.19.5750
[12]	C. T. Nguyen, A. J. Stephenson and M. W. Kattan, “Are Nomograms Needed in the Management of Bladder Cancer?” Urologic Oncology, Vol. 28, No. 1, 2010, pp. 102-107. doi:10.1016/j.urolonc.2009.04.020
[13]	A. Kutikov, et al., “Evaluating Overall Survival and Competing Risks of Death in Patients with Localized Renal Cell Carcinoma Using a Comprehensive Nomogram,” Journal of Clinical Oncology, Vol. 28, No. 2, 2010, pp. 311-317. doi:10.1200/JCO.2009.22.4816
[14]	J. Jayachandran, et al., “The Shared Equal Access Regional Cancer Hospital (SEARCH) Nomogram for risk Stratification in Intermediate Risk Group of Men with Prostate Cancer: Validation in the Duke Prostate Center Database,” BJU International, Vol. 105, No. 2, 2010, pp. 180-184. doi:10.1111/j.1464-410X.2009.08728.x
[15]	M. W. Kattan, “Nomograms Are Superior to Staging and Risk Grouping Systems for Identifying High-Risk Patients: Preoperative Application in Prostate Cancer,” Current Opinion in Urology, Vol. 13, No. 2, 2003, pp. 111-116. doi:10.1097/00042307-200303000-00005
[16]	F. K. Chun, et al., “A Critical Appraisal of Logistic Regression-Based Nomograms, Artificial Neural Networks, Classification and Regression-Tree Models, Look-Up Tables and Risk-Group Stratification Models for Prostate Cancer,” BJU International, Vol. 99, No. 4, 2007, pp. 794-800. doi:10.1111/j.1464-410X.2006.06694.x
[17]	H. K. Unruh, et al., “Women’s Approaches to the Use of New Technology for Cancer Risk Information,” Women Health, Vol. 40, No. 1, 2004, pp. 59-78. doi:10.1300/J013v40n01_04
[18]	J. L. Bevilacqua, et al., “Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation,” Journal of Clinical Oncology, Vol. 25, No. 24, 2007, pp. 3670-3679. doi:10.1200/JCO.2006.08.8013
[19]	K. J. Van Zee, et al., “A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy,” Annals of Surgical Oncology, Vol. 10, No. 10, 2003, pp. 1140-1151. doi:10.1245/ASO.2003.03.015
[20]	M. L. Smidt, et al., “Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in the Netherlands?” Annals of Surgical Oncology, Vol. 12, No. 12, 2005, pp. 1066-1072. doi:10.1245/ASO.2005.07.022
[21]	N. K. Soni, et al., “Evaluation of a Breast Cancer Nomogram for Prediction of Non-Sentinel Lymph Node Positivity,” European Journal of Surgical Oncology, Vol. 31, No. 9, 2005, pp. 958-964. doi:10.1016/j.ejso.2005.04.011
[22]	L. A. Lambert, et al., “Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases after a Positive Sentinel Node Biopsy,” Annals of Surgical Oncology, Vol. 13, No. 3, 2006, pp. 310-320. doi:10.1245/ASO.2006.03.078
[23]	A. C. Degnim, et al., “Nonsentinel Node Metastasis in Breast Cancer Patients: Assessment of an Existing and a New Predictive Nomogram,” The American Journal of Surgery, Vol. 190, No. 4, 2005, pp. 543-550. doi:10.1016/j.amjsurg.2005.06.008
[24]	A. S. Gur, et al., “Predictive Probability of Four Different Breast Cancer Nomograms for Nonsentinel Axillary Lymph Node Metastasis in Positive Sentinel Node Biopsy,” Journal of the American College of Surgeons, Vol. 208, No. 2, 2009, pp. 229-235. doi:10.1016/j.jamcollsurg.2008.10.029
[25]	M. C. Specht, et al., “Predicting Nonsentinel Node Status after Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians versus Nomogram,” Annals of Surgical Oncology, Vol. 12, No. 8, 2005, pp. 654-659. doi:10.1245/ASO.2005.06.037
[26]	M. L. Smidt, et al., “Can Surgical Oncologists Reliably Predict the Likelihood for Non-SLN Metastases in Breast Cancer Patients?” Annals of Surgical Oncology, Vol. 14, No. 2, 2007, pp. 615-620. doi:10.1245/s10434-006-9150-5
[27]	R. M. Dawes, D. Faust and P. E. Meehl, “Clinical versus Actuarial Judgment,” Science, Vol. 243, No. 4899, 1989, pp. 1668-1674. doi:10.1126/science.2648573
[28]	A. S. Elstein, “Heuristics and Biases: Selected Errors in Clinical Reasoning,” Academic Medicine, Vol. 74, No. 7, 1999, pp. 791-794. doi:10.1097/00001888-199907000-00012
[29]	U. Veronesi, et al., “A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer,” The New England Journal of Medicine, Vol. 349, No. 6, 2003, pp. 546-553. doi:10.1056/NEJMoa012782
[30]	L. K. Temple, et al., “Sensory Morbidity after Sentinel Lymph Node Biopsy and Axillary Dissection: A Prospective Study of 233 Women,” Annals of Surgical Oncology, Vol. 9, No. 7, 2002, pp. 654-662. doi:10.1007/BF02574481
[31]	M. P. Schijven, et al., “Comparison of Morbidity between Axillary Lymph Node Dissection and Sentinel Node Biopsy,” European Journal of Surgical Oncology, Vol. 29, No. 4, 2003, pp. 341-350. doi:10.1053/ejso.2002.1385
[32]	S. A. McLaughlin, et al., “Prevalence of Lymphedema in Women with Breast Cancer 5 Years after Sentinel Lymph Node Biopsy or Axillary Dissection: Patient Perceptions and Precautionary Behaviors,” Journal of Clinical Oncology, Vol. 26, No. 32, 2008, pp. 5220-5226. doi:10.1200/JCO.2008.16.3766
[33]	S. A. McLaughlin, et al., “Prevalence of Lymphedema in Women with Breast Cancer 5 Years after Sentinel Lymph Node Biopsy or Axillary Dissection: Objective Measurements,” Journal of Clinical Oncology, Vol. 26, No. 32, 2008, pp. 5213-5219. doi:10.1200/JCO.2008.16.3725
[34]	A. Lucci, et al., “Surgical Complications Associated with Sentinel Lymph Node Dissection (SLND) plus Axillary Lymph Node Dissection Compared with SLND Alone in the American College of Surgeons Oncology Group Trial Z0011,” Journal of Clinical Oncology, Vol. 25, No. 24, 2007, pp. 3657-3663. doi:10.1200/JCO.2006.07.4062
[35]	M. A. Chung, M. M. Steinhoff and B. Cady, “Clinical Axillary Recurrence in Breast Cancer Patients after a Negative Sentinel Node Biopsy,” The American Journal of Surgery, Vol. 184, No. 4, 2002, pp. 310-314. doi:10.1016/S0002-9610(02)00956-X
[36]	D. K. Blanchard, et al., “Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or with Axillary Dissection for Breast Cancer,” Archives of Surgery, Vol. 138, No. 5, 2003, pp. 482-487. doi:10.1001/archsurg.138.5.482
[37]	A. E. Giuliano, et al., “Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial,” JAMA, Vol. 305, No. 6, 2011, pp. 569-575. doi:10.1001/jama.2011.90
[38]	H. S. Cody 3rd and K. J. Van Zee, “Predicting Nonsentinel Node Metastases in Sentinel Node-Positive Breast Cancer: What Have We Learned, Can We Do Better, and Do We Need to?” Annals of Surgical Oncology, Vol. 15, No. 11, 2008, pp. 2998-3002. doi:10.1245/s10434-008-0133-6
[39]	G. H. Lyman, et al., “American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer,” Journal of Clinical Oncology, Vol. 23, No. 30, 2005, pp. 7703-7720. doi:10.1200/JCO.2005.08.001
[40]	A. Pal, et al., “A Model for Predicting Non-Sentinel Lymph Node Metastatic Disease When the Sentinel Lymph Node Is Positive,” British Journal of Surgery, Vol. 95, No. 3, 2008, pp. 302-309. doi:10.1002/bjs.5943
[41]	F. Petrelli and S. Barni, “Surgery of Primary Tumors in Stage IV Breast Cancer: An Updated Meta-Analysis of Published Studies with Meta-Regression,” Medical Oncology, Vol. 29, No. 5, 2012, pp. 3282-3290.